<DOC>
	<DOCNO>NCT02849535</DOCNO>
	<brief_summary>The rise oral targeted therapy favor outpatient care cancer patient expose new risk compare injectable chemotherapy hospital : non-adherence treatment , inappropriate management side effect interaction co-prescribed drug . The clinical consequence ( reduce efficacy potentialized toxicity ) important ambulatory monitoring treatment prescribed hospital remain underdeveloped due default coordination two setting . Adverse drug reaction major concern , , involve prescription change ( dose reduction , treatment interruption ) . This result decrease dose take risk loss efficacy . In context metastatic renal cell carcinoma , risk iatrogenicity even high oral target therapy available indication safety profile mark potentially serious toxicity ( hematologic cardiac toxicity ) know reduce treatment adherence ( digestive skin toxicity ) . In addition , molecule metabolize CYP3A4 hepatic cytochrome , lead avoid associate drug induce / inhibit CYP3A4 , risk toxicity / loss efficacy . The investigator propose assess program set secure drug take enhance self-management side effect control drug interaction patient . This program include pharmaceutical visit involve inpatient outpatient ( doctor , referent pharmacist liberal nurse ) professional . The hypothesis study PRISM care program improve self-management side effect patient , result relative dose intensity oral chemotherapy improve compare usual care .</brief_summary>
	<brief_title>Impact PRISM-care Multidisciplinary Oncology Program Secured Drug Intake Patients With Kidney Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<criteria>Patient age 18 year old With metastatic renal cell carcinoma With initiation change oral targeted therapy , especially : tyrosine kinase inhibitor ( sunitinib , sorafenib , pazopanib , axitinib ) mTor inhibitor ( everolimus ) With ambulatory status ( hospitalized management treatment metastatic renal cell carcinoma ) Without either cognitive disorder major psychiatric disorder With sufficient autonomy management medication home Having declare outpatient doctor Having declare usual pharmacy Having give write consent participate study Significant cognitive psychiatric disorder Management medication home exclusively perform family caregiver Patient institution guardianship , major protect law Patient refuse participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Oral chemotherapy</keyword>
	<keyword>Relative dose intensity</keyword>
	<keyword>Health related program</keyword>
	<keyword>Secured drug intake</keyword>
</DOC>